Did you know that one year after stopping GLP1s, many patients regain two-thirds of the weight lost? In this article, Alessandra (Ale) Vignola, President of Cardiovascular & Metabolic, explores the need for sustainable, patient-first solutions in GLP-1 clinical trials from personalized approaches to behavioral and social support. Full article here.
Alessandra (Ale) Vignola, President of Cardiovascular & Metabolic
